Analysis of the mechanism by which ketamine affects astrocytes in Parkinsonian rats through the PI3K/AKT axis.
Yanhong Xiong, Jianwen Yuan, Luogeng Xu
Cellular and molecular biology (Noisy-le-Grand, France) May 27, 2024 DOI: 10.14715/cmb/2024.70.5.29 via PubMed
Summary
AI-generated from the abstractIn a rat model of Parkinson's disease (PD), ketamine treatment alleviated behavioral deficits and brain pathology, reducing inflammation and oxidative stress. PD rats showed lower motor performance and ATPase activity, and higher α-synuclein levels. Ketamine improved these measures and suppressed the PI3K/AKT signaling pathway, promoting autophagy. Similar PI3K/AKT suppression was observed in a cell model using LPS-stimulated astrocytes. The findings suggest ketamine's potential therapeutic effects on PD are linked to inhibition of the PI3K/AKT axis.
Study at a glance
| Characteristics | Animal study Peer reviewed |
|---|---|
| Population | PD rat model (6-OHDA-induced) and astrocyte cell line HA1800 |
| Intervention | Ketamine |
| Keywords | Neuroscience Parkinsons-disease Ketamine-therapy Brain-inflammation Astrocytes |
| Citations | 1 |
| Key finding | Ketamine alleviates behavioral and pathological changes in a rat model of Parkinson's disease by inhibiting the PI3K/AKT axis and promoting autophagy. |
Abstract
Parkinson's disease (PD) remains the most common neurodegenerative disease worldwide, seriously affecting the normal life of patients. Currently, there is no effective clinical cure for PD. In this study, the research team explored the effect of ketamine (KET) on PD, which can lay a reliable foundation for future KET treatment of PD. First, the research team established a PD rat model with 6-hydroxydopamine (6-OHDA). The detection showed that the maximum angle of the inclined plate stay, the number of times of grid crossings and standing, and the ATPase activity in brain tissue were significantly lower in PD rats than in control rats, while the positive rate of α-synuclein in brain tissue was increased, showing typical pathological manifestations of PD. After using KET to intervene in PD rats, the behavioral and brain pathological changes were significantly alleviated, and the inflammation and oxidative stress damage of brain tissue were effectively reduced, suggesting the potential therapeutic effects of KET on PD. Furthermore, the use of KET inhibited the PI3K/AKT axis in the brain tissue of PD rats and promoted autophagy. Moreover, the significant suppression of the PI3K/AKT axis by KET was also demonstrated in the PD cell model established through lipopolysaccharide (LPS) inducement of astrocyte cell line HA1800. It is suggested that the mechanism of KET on PD is related to the inhibition of the PI3K/AKT axis.